Literature DB >> 11850338

An ELISA technique for quantification of surfactant apoprotein (SP)-C in bronchoalveolar lavage fluid.

Reinhold Schmidt1, Wolfram Steinhilber, Clemens Ruppert, Christina Daum, Friedrich Grimminger, Werner Seeger, Andreas Günther.   

Abstract

Pulmonary surfactant apoprotein C (SP-C) is a small, unique peptide that contributes to the reduction of alveolar surface tension. Due to the extreme hydrophobic nature of this peptide it was hitherto not possible to quantify SP-C in biological samples by immunological techniques. Using a newly developed polyclonal antibody raised against recombinant human SP-C in rabbits, we now describe an enzyme-linked immunosorbent assay (ELISA) to quantitate SP-C in bronchoalveolar lavage fluid (BALF). Solid phase binding of the hydrophobic SP-C was achieved by transfer of the standard or BALF samples (diluted in 80% isopropanol, pH 3.5) to polystyrene microtiter plates. Sequential treatment with trifluoroethanol and methanol (2x) was employed to improve antigen presentation and to minimize the influence of phospholipids. With this assay, SP-C from human, rabbit, porcine, and bovine surfactant was detectable. No cross-reactivity of the antibody to human SP-A and monomeric and dimeric SP-B was encountered. Total serum proteins did not affect ELISA signals, as evident from spiking experiments. The detection limit of the ELISA ranged below 3 ng/ml, and intra- and interassay coefficients of variation were 3.5% (n = 16) and 5.3% (n = 6), respectively. Serial dilutions of BALF showed good linearity, and excellent recovery rates were obtained upon spiking of human BALF. A mean value of 579.5 +/- 45.9 ng/ml (mean +/- SEM) SP-C was found in BALF samples of human healthy volunteers (n = 22), corresponding to 26.61 +/- 1.91 microg SP-C/mg total phospholipids (PL). SP-C levels were significantly lower in BALF of patients with acute respiratory distress syndrome (ARDS) (286.9 +/- 19.8 ng/ml [p < 0.001]; 13.92 +/- 1.93 microg SP-C/mg PL [p < 0.001], n = 48). We conclude that SP-C may be quantified with high specificity, reproducibility, and sensitivity in bronchoalveolar lavage samples by the presently described ELISA technique and that SP-C levels are significantly decreased in ARDS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850338     DOI: 10.1164/ajrccm.165.4.2102080

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  10 in total

1.  Antibody reactivity to linear epitopes of Plasmodium falciparum cytoadherence-linked asexual gene 9 in asymptomatic children and adults from papua new Guinea.

Authors:  Katharine R Trenholme; Craig S Boutlis; Rachel Kuns; Moses Lagog; Moses J Bockarie; Michelle L Gatton; David J Kemp; Michael F Good; Nicholas M Anstey; Donald L Gardiner
Journal:  Am J Trop Med Hyg       Date:  2005-06       Impact factor: 2.345

2.  Effect of surfactant protein A on the physical properties and surface activity of KL4-surfactant.

Authors:  Alejandra Sáenz; Olga Cañadas; Luís A Bagatolli; Fernando Sánchez-Barbero; Mark E Johnson; Cristina Casals
Journal:  Biophys J       Date:  2006-10-20       Impact factor: 4.033

3.  Adolescents with clinical type 1 diabetes display reduced red blood cell glucose transporter isoform 1 (GLUT1).

Authors:  Meena Garg; Manikkavasagar Thamotharan; Dorothy J Becker; Sherin U Devaskar
Journal:  Pediatr Diabetes       Date:  2014-02-19       Impact factor: 4.866

4.  Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids.

Authors:  Philipp Markart; Clemens Ruppert; Malgorzata Wygrecka; Thorsten Colaris; Bhola Dahal; Dieter Walmrath; Heinz Harbach; Jochen Wilhelm; Werner Seeger; Reinhold Schmidt; Andreas Guenther
Journal:  Thorax       Date:  2007-02-07       Impact factor: 9.139

5.  Perfluorocarbons Prevent Lung Injury and Promote Development during Artificial Placenta Support in Extremely Premature Lambs.

Authors:  Joseph T Church; Elena M Perkins; Megan A Coughlin; Jennifer S McLeod; Katherine Boss; J Kelley Bentley; Marc B Hershenson; Raja Rabah; Robert H Bartlett; George B Mychaliska
Journal:  Neonatology       Date:  2018-02-23       Impact factor: 4.035

6.  Expression profiles of hydrophobic surfactant proteins in children with diffuse chronic lung disease.

Authors:  Matthias Griese; Silja Schumacher; Mohammed Tredano; Manuela Steinecker; Annika Braun; Susan Guttentag; Michael F Beers; Michel Bahuau
Journal:  Respir Res       Date:  2005-07-22

7.  Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients.

Authors:  Matthias Griese; Robert Essl; Reinhold Schmidt; Manfred Ballmann; Karl Paul; Ernst Rietschel; Felix Ratjen
Journal:  Respir Res       Date:  2005-11-07

8.  Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration.

Authors:  Reinhold Schmidt; Philipp Markart; Clemens Ruppert; Malgorzata Wygrecka; Tim Kuchenbuch; Dieter Walmrath; Werner Seeger; Andreas Guenther
Journal:  Respir Res       Date:  2007-07-27

9.  Surfactant replacement and open lung concept--comparison of two treatment strategies in an experimental model of neonatal ARDS.

Authors:  Anne Hilgendorff; Ece Aslan; Thomas Schaible; Ludwig Gortner; Thorsten Baehner; Michael Ebsen; Jochen Kreuder; Clemens Ruppert; Andreas Guenther; Irwin Reiss
Journal:  BMC Pulm Med       Date:  2008-07-14       Impact factor: 3.317

Review 10.  Towards a biological definition of ARDS: are treatable traits the solution?

Authors:  Lieuwe D J Bos; John G Laffey; Lorraine B Ware; Nanon F L Heijnen; Pratik Sinha; Brijesh Patel; Matthieu Jabaudon; Julie A Bastarache; Daniel F McAuley; Charlotte Summers; Carolyn S Calfee; Manu Shankar-Hari
Journal:  Intensive Care Med Exp       Date:  2022-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.